Post Reply
4681-4700 of 10899
If you are uncertain that BIG is good, then sell your shares to most of us fans here who are ready to buy at the current range. Anything below 60 cents is a good buy for me.
I jsut bought 50 lots at 57 cents and not worried though it has gone down half a cent..
Cheers.
http://biosensors.listedcompany.com/newsroom/4QFY09_Briefing_Presentation_Slides.pdf?corp=us
Taken from the horses mouth... Q-2-Q is good consider some minor fluctuation in sales, it means they need to keep the eye on the ball, Forex and sales of IVP and new Biometrix.
With 2.55mm Biometrix CE marked in March, I see more reasons to support this. The coming quarters should have better sales figures, Q4 DES better than Q3, so i guess IVP has dropped. I hope they hedge the currencies. Cost is on the way down as I know they are doing it rigorously internally (grin...wink wink), so all eyes on sales and forex. Given such a consistent record, reflected by the share price curve also, no wonder analyst TP is about 90 ish before the result. I dont think TP will change much either. Whether they break into black is inmaterial as the loss is not really great, the fact is the management team is doing their bid to ensure consistency which is what good stock should have and not roller coaster, snake and ladder ride. See for yourselves the curve against the favourite hot stocks in the market (what S-chip and Genting?). DOYDD&HW.
|
Biosensors records 168% rise in FY09 revenue to US$119m
|
Tags: Biosensors International Group
|
Thursday, 28 May 2009 22:18
|
||
Biosensors International Group, which develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. today announced strong sales and earnings growth for its fourth fiscal quarter (4Q FY09) and fiscal year ended March 31, 2009 (FY09).
Total product sales in the fourth quarter were US$20.5 million ($29.75 million), a 75% increase over the same period a year ago (4Q FY08), driven largely by continued growth in the sales of BioMatrix drug‐eluting stents. |
Biosensor up too much already, not much bandwidth to go. Must buy with care, don't get trap.
Unless analyst give + + + comment. And up the fair value.
Biosensor up too much already, not much bandwidth to go. Must buy with care, don't get trap.
Unless analyst give + + + comment. And up the fair value.
2010 product revenue forecast is between 90m-100m. This is excluding royalties and licensing fees.
Here's the source: http://www.theedgesingapore.com/the-daily-edge/business/4844-biosensors-records-168-rise-in-fy09-revenue-to-us119m.html
Biosensors International Group, which develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. today announced strong sales and earnings growth for its fourth fiscal quarter (4Q FY09) and fiscal year ended March 31, 2009 (FY09).
Total product sales in the fourth quarter were US$20.5 million ($29.75 million), a 75% increase over the same period a year ago (4Q FY08), driven largely by continued growth in the sales of BioMatrix drug‐eluting stents.
For FY09, total revenue was US$119 million, a 168% increase over FY08. Of this increase, US$40 million was a one‐time, non‐recurring payment received from Terumo Corporation to reduce future revenue sharing arrangements.
In 4Q FY09, the group reported a net profit of US$0.4 million compared to a net loss of US$20.7 million in 4Q FY08.
For FY09, the company reported a net loss of US$1.1 million compared to a net loss of US$31.6 million for FY08.
The company also reported significant gross margin improvement for its interventional cardiology products for both 4Q FY09 and FY09. Product gross margins were 65% for 4Q FY09, versus 36% for 4Q FY08, and 60% for FY09 versus 39% in FY08.
******************************************************************************************************************************************************************************************************************************************************
Would like to see their q-o-q figures. G Margin improvement for ICP but how much does the ICP account for total revenue? These are all headline numbers intended to thrill. Should look @revenue streams of product line especially the much touted stent. Overall they did eke out a profit which is well and good but wat is the forward guidance? anyone?
hi, i agreed that that we should read the details carefully and we should not just assume that 1+1=2.
Without the US$40m, there won't be a US$10m tax (mainly due to the US$40m) in the 1QFY09 and the licensing fee would also be larger. There are also some one-off writedown in the 1Q & 2QFY09 due to the restructuring.
A better gauge would be to compare q-o-q instead of y-o-y or look at the 2HFY09 performance instead of the whole FY09.
read the ddetails carefully.
There is a royalty payment of $40m which is non-recurring. Without this, the loss would be $41m, and not $1m, worst than last year despite the much higher revenue.
XiaoMaGe888 ( Date: 28-May-2009 18:31) Posted:
|
BIOSENSORS INTERNATIONAL GROUP, LTD.
(Incorporated in Bermuda with limited liability)
(Company Registration Number: EC 24983)
GRANT OF OPTIONS PURSUANT TO THE BIOSENSORS EMPLOYEE SHARE OPTION SCHEME 2004
In compliance with Rule 704(27) of the SGX-Listing Manual, the Company hereby announces the following
grant of options to participants under the Biosensors Employee Share Option Scheme 2004:
(a)
(b)
The exercise price is a price equal to Market Price calculated based on the average of the last
dealt prices for the Company’s shares (as determined by reference to the daily official list or
other publication published by the SGX-ST) for the 5 consecutive market days immediately
preceding the date of grant, rounded up to the nearest whole cent and converted to US Dollars
based on the average exchange rate for the same period, rounded up to the nearest whole cent
as per the Biosensors Employee Share Option Scheme 2004.
(c)
(d)
on last done price of S$0.575.
(e)
(f)
Date of Grant: 28 May 2009Exercise price of options granted: US$0.37Total number of options granted: 1,500,000 sharesMarket price (last done price) of shares on the Date of Grant: Equivalent to US$0.397 basedNumber of options granted to directors: NoneValidity period of the options: 10 years from the Date of GrantBY ORDER OF THE BOARD
Kevin Sayer
Company Secretary
28 May 2009
XiaoMaGe888 ( Date: 28-May-2009 18:31) Posted:
|
In 4Q FY09, the Group reported a net profit of US$0.4 million (0.04 US cent earnings per basic
and diluted share) compared to a net loss of US$20.7 million (1.97 US cent loss per basic and
diluted share) in 4Q FY08. For FY09, the Company reported a net loss of US$1.1 million (0.11 US
cent loss per basic and diluted share) compared to a net loss of US$31.6 million (3.20 US cent
loss per basic and diluted share) for FY08. The decrease in net loss for the quarter was mainly
due to higher product revenue and improved gross margins, reduced operating expenses,
improved JWMS operating results offset by an exchange loss of US$3.7 million recorded in 4Q
FY09. For FY09, the decrease in loss per share was the result of the same factors that affected
4Q FY09, combined with the positive effect of the US$40.0 million of license‐related revenue
recognized in the first quarter of the fiscal year.
Financial Guidance
Typical historical tendency of BIG, going down after the results. It starts now. Clear your positions immediately. Take profit / minimise lose. BB play starts now.
My advise only to small players less than 100 lots.
Market expectation is BIG turning around to black slighly in this FY09. If it is still slightly in red, still price will be moving under .60. Well above .60 only when BIG can show a DARK BLACK.
| 14:42:18 | 0.580 | 593,000 | Buy Up |
| 14:37:53 | 0.575 | 100,000 | Sell Down |
XiaoMaGe888 ( Date: 28-May-2009 14:11) Posted:
|
Coming very soon!!!!!!!!!!!!!!!!!!!!!!!!
BIG!!!!!!!!!!!!!!!!!!!!!!!!!!CHEONG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!AR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
